Celebrating One Year of Spot On CML

Celebrating One Year of Spot On CML

The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.

These tests are critically important because a confirmed diagnosis is required for a patient to begin receiving free treatment through our donation programs – and access to treatment is access to life.

We extend our deepest thanks to the dedicated team at Fred Hutch and the hundreds of physicians and nurses around the world who work tirelessly to support their patients. Thanks to your efforts, we not only met but exceeded our initial goal – testing one new patient per day for an entire year.

Here’s how the patient numbers break down by country:

  • Bhutan – 5
  • Cambodia – 2
  • Cote d’Ivoire – 10
  • East Timor – 3
  • Fiji – 5
  • Honduras – 40
  • Kenya – 7
  • Mexico – 30
  • Mongolia – 21
  • Nepal – 95
  • Niger – 18
  • Nigeria – 10
  • Philippines – 17
  • Tajikistan – 50
  • Uganda – 58

About Spot On CML 

Launched in 2017, Spot On CML is a groundbreaking collaboration between The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries. The initiative utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

    iwCLL to provide training, medical, and programmatic guidance to support implementation of access program for innovative CLL therapy in 29 LMICs over the next three years SEATTLE, Washington – October 10, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients….

  • Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

    The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity

  • CMLPath to Care

    CMLPath to Care

    In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.